Collections

Latest programs

• Consensus or Controversy? Clinical Investigators Discuss and Debate Current Approaches to First- and Second-Line Therapy for HR-Positive Metastatic Breast Cancer

• What Clinicians Want to Know: First-Line and Maintenance Therapy for Patients with ER-Positive HER2-Positive Metastatic Breast Cancer

+15 more programs

Latest programs

• Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Genitourinary Cancers

• Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Lung Cancer

+14 more programs

Latest programs

• Expert Second Opinion: Current and Future Roles of Immunotherapy and Targeted Therapy in the Management of Advanced Gastroesophageal Cancers

• Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers

Latest programs

• ESMO Congress 2025 Review — Urothelial Bladder Cancer

• ESMO Congress 2025 Review — Prostate Cancer

+3 more programs

Latest programs

• Cases from the Community: Investigators Discuss the Role of Antibody-Drug Conjugates in the Management of Triple-Negative and HR-Positive Metastatic Breast Cancer

• 

  Cases from the Community: Investigators Discuss the Optimal Role of Endocrine-Based and Other Strategies in the Management of HR-Positive Breast Cancer

+1 more program

Latest programs

• 

  Expert Second Opinion: Investigators Discuss the Optimal Management of Myelofibrosis and Systemic Mastocytosis

• Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

+1 more program